The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become enlarged as a result of abnormal blood cell production.
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29+Reports+JAKARTA+Met+Primary+Endpoint+in+Both+Groups/8349866.html for the full story.
Sanofi (SNY) reported first quarter 2013 business earnings of 81 cents per American Depository Share (ADS), below the Zacks Consensus Estimate of 89 cents. Earnings were down 29.0% at constant exchange rates (CER) from the year-ago...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29%2C+Regeneron+%28REGN%29+Commence+COMPARE%2C+ASCERTAIN+of+Sarilumab/8339115.html for the full story.
(MedPage Today) -- New dosing recommendations for products containing zolpidem (Ambien, Ambien CR, Edluar) are now included in their labels, along with warnings of next-day hangover effects, the FDA said Tuesday.
The Centre has approved 17 proposals for foreign direct investment (FDI) worth Rs 262.56 crore, which include pharmaceutical company Sanofi’s application to invest Rs 180 crore to acquire another...
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Pharmaceutical ETF (AMEX: PPH) where we have detected an approximate $29.7 million dollar outflow -- that's a 10.9%...
Regeneron Pharmaceuticals has wagered on two preclinical programs for its growing business in ophthalmology drugs. The biotech heavyweight has forked over $20 million upfront and promised up to $45 million in milestones to its major partner Sanofi...